阿司咪唑,68844-77-9，生产厂家，价格-洛克化工网移动版

返回



基本信息

制备方法及用途

物化性质

安全信息

毒理性

MSDS

海关数据

结构与计算化学

上游产品

下游产品

阿司咪唑

中文名称：: 阿司咪唑

中文别名：: 阿司咪唑;
1-(4-氟苄基)-2-(1-[4-甲氧基苯乙基]哌啶-4-基)氨基苯并咪唑;
1-[(4-氟苯基)甲基]-N-[1-[2-(4-甲氧苯基)乙基]-4-哌啶基]-1H-苯并咪唑-2-胺

英文名称：: Astemizole

英文别名：: astemizole;
Astemizol;
1-(4-fluorophenylmethyl)-N-{1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl}-1H-benzimidazol-2-amine;
Hismanal;
Laridal;
Alermizol;
Histaminos;
1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl]benzimidazol-2-amine;
[3H]-Astemizole;
Paralergin;
1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-1H-benzimidazole-2-amine;
Astemison;
[14C]-Astemizole;
Astemizolum;
Retolen;
Hismanal(R)

CAS No.：: 68844-77-9

分子式：: C₂₈H₃₁FN₄O

分子量：: 458.58

精确分子量：: 458.24800

PSA：: 42.32000

EINECS：: 272-441-9

InChI：: The Key: GXDALQBWZGODGZ-UHFFFAOYSA-N3

危险品标志：: Xn

风险术语：: R22;R36/37/38;

安全术语：: S26;S36;

分子结构式：

SDS：: 查看

阿司咪唑制备方法及用途

制备方法

化合物(I)和碘甲烷在乙醇中回流8h,环合得到化合物(Ⅱ)。再水解脱去酯基,得到化合物(Ⅲ)。用对甲氧基苯乙基溴进行N-烷基化,得化合物(Ⅳ)。再用对氟苄基溴烷基化,得阿司咪唑。 1. 1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮的制备在反应瓶中加入2-羟基苯并咪唑5.0g(37.3mmol)和NaH 1.6g(53mmol)(NaH含量大约为80%,浸入矿物油中)的DMF 100ml的悬浮液.加毕.在60oC.(最好有N2保护)搅拌反应1h.再加入4-氟苄基氯(FBC)5.4g(37mmol),加热(60oC)搅拌反应5.5h.冷却至室温后加入冰水700ml,用二氯甲烷(500ml×2)提取.有机层用食盐水洗.无水Na2SO4干燥.过滤.滤液减压浓缩.剩余物用石油醚析晶.得1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮固体8.0g,为无色结晶mp178~179oC,收率88%. 2. 1-[(4-氟苯基)甲基]-2-氯苯并咪唑的制备在反应瓶中加入1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮5.0g(20mmol)和POCl3 28ml(300mmol),搅拌加热回流5.5h.蒸除过量的POCl3,往剩余物加入冷水600ml,用稀氨水(即NH4OH)调至碱性,析出沉淀,过滤收集,用石油醚/二氯甲烷(2:1)重结晶,得无色结晶1-[(4-氟苯基)甲基]-2-氯苯并咪唑4.4g,收率84%,mp75~76oC. 3. 4-[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯的制备在反应瓶中加入1-[(4-氟苯基)甲基]-2-氯苯并咪唑3.32g(12.7mmol)和4-氨基-1-哌啶羧酸乙酯4.2g(26.4mmol),在氩气保护下搅拌升温至125 oC,在该温度搅拌反应5h.冷却后加入10%NaOH水溶液60ml ,混合物用二氯甲烷提取,有机层用食盐水洗,无水Na2SO4干燥,过滤,滤液浓缩至干(减压下),剩余固体用闪式(快速)色谱法提纯,以二氯甲烷洗脱(固体粗品也用二氯甲烷调配进柱) ,得到固体用二氯甲烷/二异丙醚(2:1)重结晶,得4[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯无色结晶2.82g,收率56%,mp179~180oC. 4. 1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐的制备在反应瓶中加入4-[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯2.1g(5.3mmol)和48%氢溴酸130ml,强烈搅拌下加热,搅拌回流1h.真空下蒸除过量的氢溴酸,剩余物用2-丙醇结晶,得1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐2.5g,收率95%,mp280 oC. 5. 阿司咪唑的合成在反应瓶中加入1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐4.86g(10mmol)、NaH1.2g(80%含量#浸入矿物油中)和KI1.7g(10mmol)悬浮于DMF100ml的悬浮液,搅拌升温至70 oC(在氩气保护下),在该温度下搅拌反应10h,然后加入4-甲氧基苯乙基氯1.71g(10mmol),连续搅拌加热(60~70 oC)反应2h.冷却后,加入10%NaOH水溶液100ml,产生沉淀,过滤,用二异丙醚重结晶得阿司咪唑2.3g,收率50%,

合成制备方法

化合物(I)和碘甲烷在乙醇中回流8h，环合得到化合物(Ⅱ)。再水解脱去酯基，得到化合物(Ⅲ)。用对甲氧基苯乙基溴进行N-烷基化，得化合物(Ⅳ)。再用对氟苄基溴烷基化，得阿司咪唑。

1. 1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮的制备

在反应瓶中加入2-羟基苯并咪唑5.0g(37.3mmol)和NaH 1.6g(53mmol)(NaH含量大约为80%,浸入矿物油中)的DMF 100ml的悬浮液.加毕.在60ºC.(最好有N2保护)搅拌反应1h.再加入4-氟苄基氯(FBC)5.4g(37mmol),加热(60ºC)搅拌反应5.5h.冷却至室温后加入冰水700ml,用二氯甲烷(500ml×2)提取.有机层用食盐水洗.无水Na2SO4干燥.过滤.滤液减压浓缩.剩余物用石油醚析晶.得1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮固体8.0g,为无色结晶mp178~179ºC,收率88%.

2. 1-[(4-氟苯基)甲基]-2-氯苯并咪唑的制备

在反应瓶中加入1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮5.0g(20mmol)和POCl3 28ml(300mmol),搅拌加热回流5.5h.蒸除过量的POCl3,往剩余物加入冷水600ml,用稀氨水(即NH4OH)调至碱性,析出沉淀,过滤收集,用石油醚/二氯甲烷(2:1)重结晶,得无色结晶1-[(4-氟苯基)甲基]-2-氯苯并咪唑4.4g,收率84%,mp75~76ºC.

3. 4-[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯的制备

在反应瓶中加入1-[(4-氟苯基)甲基]-2-氯苯并咪唑3.32g(12.7mmol)和4-氨基-1-哌啶羧酸乙酯4.2g(26.4mmol),在氩气保护下搅拌升温至125 ºC,在该温度搅拌反应5h.冷却后加入10%NaOH水溶液60ml ,混合物用二氯甲烷提取,有机层用食盐水洗,无水Na2SO4干燥,过滤,滤液浓缩至干(减压下),剩余固体用闪式(快速)色谱法提纯,以二氯甲烷洗脱(固体粗品也用二氯甲烷调配进柱) ,得到固体用二氯甲烷/二异丙醚(2:1)重结晶,得4[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯无色结晶2.82g,收率56%,mp179~180ºC.

4. 1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐的制备

在反应瓶中加入4-[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯2.1g(5.3mmol)和48%氢溴酸130ml,强烈搅拌下加热,搅拌回流1h.真空下蒸除过量的氢溴酸,剩余物用2-丙醇结晶,得1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐2.5g,收率95%,mp280 ºC.

5. 阿司咪唑的合成

在反应瓶中加入1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐4.86g(10mmol)、NaH1.2g(80%含量#浸入矿物油中)和KI1.7g(10mmol)悬浮于DMF100ml的悬浮液,搅拌升温至70 ºC(在氩气保护下),在该温度下搅拌反应10h,然后加入4-甲氧基苯乙基氯1.71g(10mmol),连续搅拌加热(60~70 ºC)反应2h.冷却后,加入10%NaOH水溶液100ml,产生沉淀,过滤,用二异丙醚重结晶得阿司咪唑2.3g,收率50%,

用途简介

新H1组胺受体拮抗剂.可选择性作用于组胺Hl受体,结合力强于常规抗组胺药,且持续时间长.适用于慢性荨麻疹、枯草热、季节性过敏性鼻炎、过敏性结膜炎、过敏性哮喘等的治疗. 本品属新型组胺Hl受体拮抗剂,可选择性作用组胺Hl受体,结合力强于常规抗组胺药,且持续时间长,但睡意镇静作用弱.用于慢性荨麻疹、枯草热、季节性过敏性鼻炎、过敏性结膜炎、过敏性哮喘等的治疗.

用途

新H1组胺受体拮抗剂.可选择性作用于组胺Hl受体,结合力强于常规抗组胺药,且持续时间长.适用于慢性荨麻疹、枯草热、季节性过敏性鼻炎、过敏性结膜炎、过敏性哮喘等的治疗.

本品属新型组胺Hl受体拮抗剂,可选择性作用组胺Hl受体,结合力强于常规抗组胺药,且持续时间长,但睡意镇静作用弱.用于慢性荨麻疹、枯草热、季节性过敏性鼻炎、过敏性结膜炎、过敏性哮喘等的治疗.

阿司咪唑物化性质

外观与性状：
白色粉末

密度：
1.2 g/cm3

熔点：
172.9ºC

沸点：
627.3ºC at 760 mmHg

闪点：
333.2ºC

折射率：
1.623

存储条件/存储方法：
通风低温干燥,与库房食品原料分开存放

稳定性相关：

远离氧化物。

其它信息：

1.       性状：白色结晶。
2.       密度（g/mL,25/4℃）：未确定
3.       相对蒸汽密度（g/mL,空气=1）：未确定
4.       熔点（ºC）：172.9
5.       沸点（ºC,常压）：未确定
6.       沸点（ºC,5.2kPa）：未确定
7.       折射率：未确定
8.       闪点（ºC）：未确定
9.       比旋光度（º）：未确定
10.    自燃点或引燃温度（ºC）：未确定
11.    蒸气压（kPa,25ºC）：未确定
12.    饱和蒸气压（kPa,60ºC）：未确定
13.    燃烧热（KJ/mol）：未确定
14.    临界温度（ºC）：未确定
15.    临界压力（KPa）：未确定
16.    油水（辛醇/水）分配系数的对数值：未确定
17.    爆炸上限（%,V/V）：未确定
18.    爆炸下限（%,V/V）：未确定
19.    溶解性：几乎不溶于水。

阿司咪唑安全信息

海关代码：
2933990090

WGK_Germany：
3
德国有关水污染物质的分类清单

危险类别码：
R22;R36/37/38

安全说明：
S26-S36

RTECS号：
DD8968000

安全标志：
S26:万一接触眼睛，立即使用大量清水冲洗并送医诊治。
S36:穿戴合适的防护服装。

危险标志：
Xn: Harmful;

阿司咪唑毒理性

CHEMICAL IDENTIFICATION

RTECS NUMBER :
DD8968000

CHEMICAL NAME :
Benzimidazole, 1-(p-fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)pi perid-4-yl)amino)-

CAS REGISTRY NUMBER :
68844-77-9

LAST UPDATED :
199703

DATA ITEMS CITED :
14

MOLECULAR FORMULA :
C28-H31-F-N4-O

MOLECULAR WEIGHT :
458.63

WISWESSER LINE NOTATION :
T56 BN DNJ B1R DF& CM- DT6NTJ A2R DO1
HEALTH HAZARD DATA
ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
5400 ug/kg

TOXIC EFFECTS :
Behavioral - general anesthetic Cardiac - EKG changes not diagnostic of specified effects Cardiac - pulse rate increase, without fall in BP

REFERENCE :
PECAE5 Pediatric Emergency Care. (Williams & Wilkins, 428 E. Preston St., Baltimore, MD 21202) V.1- 1985- Volume(issue)/page/year: 9,23,1993

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
4 mg/kg

TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)

REFERENCE :
HUTODJ Human Toxicology. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants., RG 21 2XS, UK) V.1- 1981- Volume(issue)/page/year: 5,43,1986

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
4 mg/kg

TOXIC EFFECTS :
Behavioral - coma Cardiac - arrhythmias (including changes in conduction) Gastrointestinal - nausea or vomiting

REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 292,660,1986

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
4 mg/kg

TOXIC EFFECTS :
Cardiac - change in rate

REFERENCE :
JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 31,121,1993

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
>2560 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
355 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,381,1983

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
28200 ug/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,381,1983

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
2560 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
1928 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,239,1995

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
35 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,239,1995

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
>320 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
21800 ug/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,381,1983

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - guinea pig

DOSE/DURATION :
933 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981 ** REPRODUCTIVE DATA **

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Subcutaneous

DOSE :
220 mg/kg

SEX/DURATION :
female 1-22 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - physical

REFERENCE :
CBPCEE Comparative Biochemistry and Physiology, C: Pharmacology, Toxicology and Endocrinology. (Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.74- 1983- Volume(issue)/page/year: 114,123,1996

毒理学数据：

急性毒性LD50大鼠(mg/kg):>2560口服。

阿司咪唑 MSDS

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
  Product identifiers
    Product name        : Astemizole
    CAS-No.        : 68844-77-9
  Relevant identified uses of the substance or mixture and uses advised against
    Identified uses        : Laboratory chemicals, Manufacture of substances



Section 2. HAZARDS IDENTIFICATION
  Classification of the substance or mixture
  Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
    Skin irritation (Category 2)
    Eye irritation (Category 2)
    Specific target organ toxicity - single exposure (Category 3)
  Classification according to EU Directives 67/548/EEC or 1999/45/EC
    Harmful if swallowed. Irritating to eyes, respiratory system and skin.
  Label elements
  Labelling according Regulation (EC) No 1272/2008 [CLP]
    Pictogram
    Signal word        Warning
    Hazard statement(s)
    H315        Causes skin irritation.
    H319        Causes serious eye irritation.
    H335        May cause respiratory irritation.
    Precautionary statement(s)
    P261        Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
    P305 + P351 + P338        IF IN EYES: Rinse cautiously with water for several minutes. Remove
    contact lenses, if present and easy to do. Continue rinsing.
    Supplemental Hazard        none
    Statements
  According to European Directive 67/548/EEC as amended.
    Hazard symbol(s)
    R-phrase(s)
    R22        Harmful if swallowed.
    R36/37/38        Irritating to eyes, respiratory system and skin.
    S-phrase(s)
    S26        In case of contact with eyes, rinse immediately with plenty of water and
    seek medical advice.
    S36        Wear suitable protective clothing.
  Other hazards - none

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
  Substances
    Formula        : C28H31FN4O
    Molecular Weight        : 458,57 g/mol
    Component        Concentration
  Astemizole
    CAS-No.        68844-77-9        -
    EC-No.        272-441-9

Section 4. FIRST AID MEASURES
  Description of first aid measures
  General advice
    Consult a physician. Show this safety data sheet to the doctor in attendance.
  If inhaled
    If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
  In case of skin contact
    Wash off with soap and plenty of water. Consult a physician.
  In case of eye contact
    Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
  If swallowed
    Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
  Most important symptoms and effects, both acute and delayed
  Indication of any immediate medical attention and special treatment needed
    no data available

Section 5. FIREFIGHTING MEASURES
  Extinguishing media
  Suitable extinguishing media
    Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
  Special hazards arising from the substance or mixture
    Carbon oxides, nitrogen oxides (NOx), Hydrogen fluoride
  Advice for firefighters
    Wear self contained breathing apparatus for fire fighting if necessary.
  Further information
    no data available

Section 6. ACCIDENTAL RELEASE MEASURES
  Personal precautions, protective equipment and emergency procedures
    Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
    adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
  Environmental precautions
    Do not let product enter drains.
  Methods and materials for containment and cleaning up
    Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
    containers for disposal.
  Reference to other sections
    For disposal see section 13.

Section 7. HANDLING AND STORAGE
  Precautions for safe handling
    Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
    Provide appropriate exhaust ventilation at places where dust is formed.
  Conditions for safe storage, including any incompatibilities
    Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
    Recommended storage temperature: 2 - 8 °C
    Store with desiccant. Light sensitive.
  Specific end uses
    no data available

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
  Control parameters
  Components with workplace control parameters
  Exposure controls
  Appropriate engineering controls
    Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
    at the end of workday.
  Personal protective equipment
  Eye/face protection
    Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
    and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
  Skin protection
    Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
    (without touching glove's outer surface) to avoid skin contact with this product. Dispose of
    contaminated gloves after use in accordance with applicable laws and good laboratory practices.
    Wash and dry hands.
    The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
    the standard EN 374 derived from it.
  Body Protection
    impervious clothing, The type of protective equipment must be selected according to the
    concentration and amount of the dangerous substance at the specific workplace.
  Respiratory protection
    For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
    level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
    Use respirators and components tested and approved under appropriate government standards
    such as NIOSH (US) or CEN (EU).

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
  Information on basic physical and chemical properties
    a) Appearance        Form: solid
    b) Odour        no data available
    c) Odour Threshold        no data available
    d) pH        no data available
    e) Melting point/freezing        no data available
    point
    f) Initial boiling point and no data available
    boiling range
    g) Flash point        no data available
    h) Evaporation rate        no data available
    i) Flammability (solid, gas) no data available
    j) Upper/lower        no data available
    flammability or
    explosive limits
    k) Vapour pressure        no data available
    l) Vapour density        no data available
    m) Relative density        no data available
    n) Water solubility        no data available
    o) Partition coefficient: n- no data available
    octanol/water
    p) Autoignition        no data available
    temperature
    q) Decomposition        no data available
    temperature
    r) Viscosity        no data available
    s) Explosive properties        no data available
    t) Oxidizing properties        no data available
  Other safety information
    no data available

Section 10. STABILITY AND REACTIVITY
  Reactivity
    no data available
  Chemical stability
    no data available
  Possibility of hazardous reactions
    no data available
  Conditions to avoid
    no data available
  Incompatible materials
    no data available
  Hazardous decomposition products
    Other decomposition products - no data available

Section 11. TOXICOLOGICAL INFORMATION
  Information on toxicological effects
  Acute toxicity
    LD50 Oral - rat - > 2.560 mg/kg
    Inhalation: Irritating to respiratory system.
  Skin corrosion/irritation
    no data available
  Serious eye damage/eye irritation
    no data available
  Respiratory or skin sensitization
    no data available
  Germ cell mutagenicity
    no data available
  Carcinogenicity
    IARC:        No component of this product present at levels greater than or equal to 0.1% is identified as
    probable, possible or confirmed human carcinogen by IARC.
  Reproductive toxicity
    Reproductive toxicity - rat - Subcutaneous
    Effects on Newborn: Growth statistics (e.g., reduced weight gain). Effects on Newborn: Behavioral. Effects
    on Newborn: Physical.
  Specific target organ toxicity - single exposure
    Inhalation - May cause respiratory irritation.
  Specific target organ toxicity - repeated exposure
    no data available
  Aspiration hazard
    no data available
  Potential health effects
  Inhalation        May be harmful if inhaled. Causes respiratory tract irritation.
  Ingestion        May be harmful if swallowed.
  Skin        May be harmful if absorbed through skin. Causes skin irritation.
  Eyes        Causes serious eye irritation.
  Additional Information
    RTECS: DD8968000

Section 12. ECOLOGICAL INFORMATION
  Toxicity
    no data available
  Persistence and degradability
    no data available
  Bioaccumulative potential
    no data available
  Mobility in soil
    no data available
  Results of PBT and vPvB assessment
    no data available
  Other adverse effects
    no data available

Section 13. DISPOSAL CONSIDERATIONS
  Waste treatment methods
  Product
    Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
    with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
  Contaminated packaging
    Dispose of as unused product.

Section 14. TRANSPORT INFORMATION
  UN number
    ADR/RID: -        IMDG: -        IATA: -
  UN proper shipping name
    ADR/RID: Not dangerous goods
    IMDG: Not dangerous goods
    IATA:        Not dangerous goods
  Transport hazard class(es)
    ADR/RID: -        IMDG: -        IATA: -
  Packaging group
    ADR/RID: -        IMDG: -        IATA: -
  Environmental hazards
    ADR/RID: no        IMDG Marine pollutant: no        IATA: no
  Special precautions for user
    no data available

Section 15. REGULATORY INFORMATION
    This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
  Safety, health and environmental regulations/legislation specific for the substance or mixture
    no data available
  Chemical Safety Assessment
    no data available

Section 16. OTHER INFORMATION
  Further information
    Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
    only.
    The above information is believed to be correct but does not purport to be all inclusive and shall be
    used only as a guide. The information in this document is based on the present state of our knowledge
    and is applicable to the product with regard to appropriate safety precautions. It does not represent any
    guarantee of the properties of the product. Corporation and its Affiliates shall not be held
    liable for any damage resulting from handling or from contact with the above product. See
     and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

阿司咪唑海关数据

中国海关编码：2933990090

概述：

2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

申报要素：

品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

摘要/Summary：

2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

阿司咪唑分子结构与计算化学数据

分子结构数据

1、   摩尔折射率：133.94
2、   摩尔体积（cm³/mol）：379.8
3、   等张比容（90.2K）：981.0
4、   表面张力（dyne/cm）：44.5
5、   极化率（10^-24cm³）：53.09

计算化学数据

1.疏水参数计算参考值（XlogP）:6
2.氢键供体数量:1
3.氢键受体数量:5
4.可旋转化学键数量:8
5.互变异构体数量:2
6.拓扑分子极性表面积42.3
7.重原子数量:34
8.表面电荷:0
9.复杂度:599
10.同位素原子数量:0
11.确定原子立构中心数量:0
12.不确定原子立构中心数量:0
13.确定化学键立构中心数量:0
14.不确定化学键立构中心数量:0
15.共价键单元数量:1

阿司咪唑上游产品

1-丙基-3-吡啶-2-基硫代脲 4-methoxyphenyl ethanolmethanesulfonate ester 1-[(4-氟苯基)甲基]-N-(4-哌啶基-1H-苯并咪唑-2-胺二氢溴酸盐三氯甲烷 4-[[1-[(4-氟苯基)甲基]-1H-苯并咪唑-2-基]氨基]哌啶-1-甲酸乙酯

阿司咪唑下游产品

1-丙基-3-吡啶-2-基硫代脲诺阿斯米唑 6-Hydroxydesmethylastemizole

推荐供应商

湖北万得化工有限公司

阿司咪唑
联系人：王念
电  话：027-59210159
手  机：15172311821
Cas号：68844-77-9
包装：1kg铝箔袋/氟化瓶,10kg铝听/纸箱,25kg纸板桶/编织袋/塑料桶,200kg镀锌铁桶/塑料桶,1t吨袋
纯度：99%
价格：1.0元 - 1,000.0元
湖北巨胜科技有限公司

阿司咪唑
联系人：孙敏
电  话：027-59599240
手  机：18702754003
Cas号：68844-77-9
包装：25kg纸板桶/编织袋/塑料桶
纯度：99%
价格：25.0元
湖北信康医药化工有限公司

阿司咪唑
联系人：张经理
电  话：027-59308705
手  机：18827031272
Cas号：68844-77-9
包装：25kg纸板桶/编织袋/塑料桶
纯度：99%
价格：25.0元
淄博航宇生物科技发展有限公司

阿司咪唑
联系人：张经理
电  话：15666366704
手  机：15666366704
Cas号：68844-77-9
包装：100kg
纯度：99%
价格：洽谈
上海吉至生化科技有限公司

阿司咪唑
联系人：Shirley张
电  话：021-57520831
手  机：18116052675
Cas号：68844-77-9
包装：10mgea
纯度：98%
价格：78.0元
湖北拓邦化工有限公司

阿司咪唑
联系人：胡雯丽
电  话：027-59106185
手  机：13986181695
Cas号：68844-77-9
包装：10kg
纯度：99%
价格：洽谈
湖北达豪化工有限公司

阿司咪唑
联系人：刘紫莹
电  话：027-59106191
手  机：13986246535
Cas号：68844-77-9
包装：10kg
纯度：99%
价格：洽谈
湖北成海化工有限公司

阿司咪唑
联系人：张思胧
电  话：027-59220433
手  机：13986212397
Cas号：68844-77-9
包装：10kg
纯度：99%
价格：洽谈
湖北广奥生物科技有限公司

阿司咪唑
联系人：付玉
电  话：027-59223056
手  机：15271829679
Cas号：68844-77-9
包装：1kg铝箔袋/氟化瓶,10kg铝听/纸箱,25kg纸板桶/编织袋/塑料桶,200kg镀锌铁桶/塑料桶,1t吨袋
纯度：99%
价格：1.0元 - 1,000.0元
上海源叶生物科技有限公司

68844-77-9
联系人：Yuki
电  话：021-61845781
手  机：13585604150
Cas号：68844-77-9
包装：5mg,10mg,25mg
纯度：98%
价格：180.0元 - 500.0元

阿司咪唑

阿司咪唑 制备方法及用途

制备方法

合成制备方法

用途简介

用途

阿司咪唑 物化性质

阿司咪唑 安全信息

阿司咪唑 毒理性

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

阿司咪唑 MSDS

阿司咪唑 海关数据

中国海关编码：2933990090

阿司咪唑 分子结构与计算化学数据

分子结构数据

计算化学数据

阿司咪唑 上游产品

阿司咪唑 下游产品

推荐供应商

湖北万得化工有限公司

阿司咪唑

湖北巨胜科技有限公司

阿司咪唑

湖北信康医药化工有限公司

阿司咪唑

淄博航宇生物科技发展有限公司

阿司咪唑

上海吉至生化科技有限公司

阿司咪唑

湖北拓邦化工有限公司

阿司咪唑

湖北达豪化工有限公司

阿司咪唑

湖北成海化工有限公司

阿司咪唑

湖北广奥生物科技有限公司

阿司咪唑

上海源叶生物科技有限公司

68844-77-9

阿司咪唑制备方法及用途

阿司咪唑物化性质

阿司咪唑安全信息

阿司咪唑毒理性

阿司咪唑海关数据

阿司咪唑分子结构与计算化学数据

阿司咪唑上游产品

阿司咪唑下游产品